Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
Journal of Traditional Chinese Medicine ; (12): 50-54, 2024.
Article in Chinese | WPRIM | ID: wpr-1005110

ABSTRACT

This paper summarized the key points and methods in terms of the establishment of the guideline working group and the management of conflict of interests, trying to provide reference for the development of clinical practice guidelines for Chinese patent medicine (CPM). The establishment of the working group is the first important step for developing CPM guidelines. Considering the characteristics of the clinical practice guidelines for CPM, this study suggests that the three key elements of ‘multidisciplinarity’, ‘clinical relevance’ and ‘geographical representativeness’ should be put focus on when forming the working group. The guideline advisory committee, clinical expert group, evidence systematic evaluation group, secretary group and the external review group should be established. All group members should clarify the conflict of interest, and the process and management method of the conflict of interest should be clearly reported.

2.
Rev. panam. salud pública ; 46: e95, 2022. tab
Article in Spanish | LILACS-Express | LILACS | ID: biblio-1450201

ABSTRACT

RESUMEN El presente informe especial describe tanto la metodología para el cálculo del indicador sobre adopción de mecanismos eficaces para evitar la interferencia de la industria tabacalera o de aquellos que defienden sus intereses, establecido en la "Estrategia y plan de acción para fortalecer el control del tabaco en la Región de las Américas 2018-2022", así como del estado de adopción de estos mecanismos en los países de la Región para el año 2019, y su progreso desde 2016. Se encontró que, para el 2019, de los 35 Estados Miembros de la Organización Panamericana de la Salud (OPS), 13 cuentan con normativa que establece medidas específicas al manejo de conflicto de interés para funcionarios y empleados públicos con competencia en políticas de control del tabaco. Asimismo, 7 han implementado medidas relacionadas, pero no específicas, y 14 no han implementado ninguna medida. Si bien se muestra un avance en relación con año 2016, los esfuerzos deben ser redoblados para alcanzar la meta de 20 Estados Miembros con mecanismos de identificación y manejo de conflictos de interés, establecida en la Estrategia y plan de acción. Cabe destacar que contar con normativa referida al tema no agota, ni mucho menos, concluye el cumplimiento de todas las obligaciones que emanan del artículo 5.3 del Convenio Marco de la Organización Mundial de la Salud para el Control del Tabaco. La Secretaría de OPS, en cumplimiento de lo solicitado por los Estados Miembros, desarrolló la metodología para el cálculo del indicador y sistematizó los hallazgos que son presentados.


ABSTRACT This special report describes the methodology for calculating the indicator for the adoption of effective mechanisms to counter interference by the tobacco industry and those who work to further its interests, as established in the Strategy and Plan of Action to Strengthen Tobacco Control in the Region of the Americas 2018-2022; the report also presents the status of adoption of these mechanisms in the countries of the Region as of 2019, and progress since 2016. It was found that, as of 2019, of the 35 Pan American Health Organization (PAHO) Member States 13 had regulations establishing specific measures for managing conflicts of interest for government officials and employees with responsibility for tobacco control policies; seven had implemented related but nonspecific measures; and 14 had not implemented any measure. Although there has been progress since 2016, efforts must be redoubled to reach the target of 20 Member States having mechanisms for the identification and management of conflicts of interest, as established in the Strategy and Plan of Action. It should be noted that having regulations on the subject does not fulfill, nor by any means fully meet, all the obligations arising from Article 5.3 of the World Health Organization Framework Convention on Tobacco Control. The PAHO Secretariat, in response to requests by Member States, developed the methodology for calculation of the indicator and systematized the findings that are presented.


RESUMO Este relatório especial descreve tanto a metodologia de cálculo do indicador sobre a adoção de mecanismos eficazes para evitar a interferência da indústria do tabaco ou daqueles que defendem seus interesses, estabelecida na "Estratégia e plano de ação para fortalecer o controle do tabagismo na Região das Américas 2018-2022", quanto a situação da adoção desses mecanismos nos países da Região para o ano de 2019, e seu progresso desde 2016. Constatou-se que, até 2019, dos 35 Estados Membros da Organização Pan-Americana da Saúde (OPAS), 13 possuíam regulamentações que estabelecem medidas específicas para o manejo de conflitos de interesse para funcionários públicos responsáveis por políticas de controle do tabaco. Da mesma forma, 7 haviam implementado medidas relacionadas, mas não específicas, e 14 não haviam implementado nenhuma medida. Embora haja avanços em relação a 2016, os esforços devem ser redobrados para atingir a meta estabelecida na estratégia e no plano de ação de 20 Estados Membros com mecanismos de identificação e gestão de conflitos de interesse. Vale destacar que ter regulamentação sobre o tema não esgota, muito menos conclui, o cumprimento de todas as obrigações que emanam do artigo 5.3 da Convenção-Quadro da Organização Mundial da Saúde para o Controle do Tabaco. A Secretaria da OPAS, em cumprimento ao que foi solicitado pelos Estados Membros, desenvolveu a metodologia para o cálculo do indicador e sistematizou os resultados aqui apresentados.

3.
Cad. Saúde Pública (Online) ; 37(supl.1): e00195520, 2021. tab
Article in Portuguese | LILACS | ID: biblio-1374802

ABSTRACT

As ações de promoção da alimentação saudável são estratégicas para reversão dos problemas nutricionais. Este artigo analisa as disputas em torno das ideias presentes em repertórios discursivos sobre alimentação saudável em políticas nacionais, documentos internacionais, societários e do setor privado comercial, nos últimos vinte anos. Com base no método de análise documental em diálogo com a literatura acadêmica, foram identificadas as seguintes perspectivas de alimentação saudável: tradicional culturalista; nutricional biologicista medicalizante; multidimensional e sistêmica. As disputas instituem-se em torno das ideias sobre: a existência de "alimentos não saudáveis"; as atribuições, limites e formas de intervenção do Estado; a alimentação como uma questão da esfera individual ou de caráter público; os sentidos da sustentabilidade, da comensalidade, da cultura e da comida. Os posicionamentos adotados nas políticas em relação aos agrotóxicos, à fortificação de alimentos e à suplementação são elementos-chave dessas disputas. No âmbito da ação política, a fragmentação, a relativização e a distorção de significados são estratégias adotadas pelo setor privado comercial que reforçam a polarização entre ações individuais (estilos de vida, liberdade de escolha) e intervenções ambientais, e disseminam uma concepção restrita de educação alimentar e nutricional. A sociedade civil incide politicamente pressionando os governos a instituírem, em suas políticas, concepções e princípios que afetam diretamente os parâmetros das disputas. Estes, por sua vez, agem de forma mais ou menos permeável às pressões dos atores (internos ou externos) a depender de sua composição e dos espaços institucionais de interlocução com a sociedade.


Las acciones de promoción de la alimentación saludable son estratégicas para la reversión de los problemas nutricionales. Este artículo analiza las disputas en torno a las ideas presentes en repertorios discursivos sobre alimentación saludable en políticas nacionales, documentos internacionales, societarios y del sector privado comercial, en los últimos 20 años. En base al método de análisis documental, en diálogo con la literatura académica, se identificaron las siguientes perspectivas de alimentación saludable: tradicional-cultural; nutricional-biologicista-medicalizante; multidimensional y sistémica. Las disputas se instituyen en torno a las ideas sobre: la existencia de "alimentos no saludables"; las atribuciones, límites y formas de intervención del Estado; la alimentación como una cuestión de la esfera individual o de carácter público; los significados de la sostenibilidad, comensalidad, cultura y comida. Las posturas adoptadas en las políticas, relacionadas con los pesticidas, fortificación de alimentos y suplementación, son elementos-clave de esas disputas. En el ámbito de la acción política, la fragmentación, relativización y distorsión de significados son estrategias adoptadas por el sector privado comercial, que refuerzan la polarización entre acciones individuales (estilos de vida, libertad de elección) e intervenciones ambientales, y diseminan una concepción restringida de educación alimentaria y nutricional. La sociedad civil incide políticamente, presionando a los gobiernos a que instituyan en sus políticas concepciones y principios que afectan directamente los parámetros de las disputas. Estos, a su vez, actúan de forma más o menos permeable a las presiones de los actores (internos o externos) dependiendo de su composición y de los espacios institucionales de interlocución con la sociedad.


Actions in the promotion of healthy eating are strategic for reversing nutritional problems. This article analyzes the disputes over ideas in discursive repertoires on healthy eating in Brazil's national policies and international, government, civil society, and private commercial sector documents in the last 20 years. Based on the document analysis method in dialogue with the academic literature, the following perspectives on healthy eating were identified: traditional culturalist; medicalizing biological/nutritional; multidimensional; and systemic. The disputes are established between ideas in the following areas: the existence of "unhealthy foods"; the attributions, limits, and forms of State intervention; eating as an individual or public matter; and the meanings of sustainability, commensality, culture, and food. Policy positions on pesticides, food fortification, and supplementation are key elements in these disputes. In the policy sphere, the private commercial sector adopts strategies of fragmentation, downplaying, and distortion of meanings that reinforce polarization between individual actions (lifestyles, freedom of choice) and environmental interventions, thereby disseminating a narrow approach to food and nutrition education. Civil society pressures governments to establish concepts and principles in policies that directly affect the disputes' parameters. The latter act with greater or lesser permeability to pressures from internal or external stakeholders, depending on their composition and the institutional spaces for dialogue with society.


Subject(s)
Humans , Dissent and Disputes , Diet, Healthy , Brazil , Health Education , Government
4.
Gac. méd. Méx ; 156(6): 556-562, nov.-dic. 2020. tab
Article in Spanish | LILACS | ID: biblio-1249967

ABSTRACT

Resumen Introducción: La relación médico-industria farmacéutica (IF) se ha identificado como un problema ético por favorecer conflictos de interés derivados de los beneficios que reciben los médicos y que pueden afectar su juicio clínico. Objetivo: Identificar la frecuencia de participación de médicos en actividades financiadas por la IF, las actitudes de estos profesionales hacia los representantes de la IF, su conducta prescriptiva y la asociación de sus características y del trabajo con la participación en actividades financiadas por la IF. Método: Encuesta transversal a médicos internistas y cardiólogos. El cuestionario incluyó características de los médicos y centro de trabajo, participación en actividades financiadas por la IF, actitudes hacia los representantes y conducta de prescripción. Resultados: Se analizaron 455 cuestionarios, 78.5 % de los encuestados tuvo conocimiento de la relación médico-IF, la mayoría respondió reunirse con representantes de la IF, 30 % indicó haber recibido subsidios financieros y 10 % consideró que los obsequios afectan su prescripción. Tener conocimiento previo de la relación médico-IF se asoció con menor participación en actividades educativas financiadas por por la IF. Conclusión: Las prácticas y preferencias hacia la IF muestran la necesidad de diseñar estrategias para evitar la prescripción inapropiada.


Abstract Introduction: The physician-pharmaceutical industry relationship has been identified as an ethical problem, due to conflicts of interest motivated by the benefits that doctors receive and that can affect their clinical judgment. Objective: To identify the frequency of physicians participation in activities financed by the pharmaceutical industry (PI), their attitudes towards PI representatives (PIRs), their prescriptive behavior and the association between their characteristics and their workplace with their participation in activities financed by the PI. Method: Cross-sectional survey to internists and cardiologists. The questionnaire included characteristics of the doctors and their workplace, participation in activities financed by the PI, attitudes towards PIRs, and prescription behavior. Results: 455 questionnaires were analyzed; 78.5 % of surveyed subjects were aware of the physician-PI relationship, the majority acknowledged meeting with PIRs, 30 % indicated having received financial subsidies and 10 % considered that gifts affect their prescription. Having prior knowledge of the physician-PI relationship was associated with less participation in PI-financed educational activities. Conclusion: Practices and preferences towards the PI show the need to design strategies to avoid inappropriate prescription.


Subject(s)
Humans , Male , Female , Physicians/ethics , Drug Prescriptions , Practice Patterns, Physicians' , Attitude of Health Personnel , Conflict of Interest , Drug Industry/ethics , Cross-Sectional Studies , Workplace , Health Care Surveys/statistics & numerical data , Gift Giving/ethics , Inappropriate Prescribing/prevention & control , Cardiologists/ethics , Habits , Internal Medicine/ethics
5.
Chinese Journal of Hospital Administration ; (12): 846-848, 2019.
Article in Chinese | WPRIM | ID: wpr-796488

ABSTRACT

With the constant growth of national investment in science and technology, biomedical scientific and technological achievements keep mushrooming. Hospitals, as a powerful force in high-tech research and development, experimental translation and industrialization of biomedicine research, play an important role in the transfer and translation of scientific and technological achievements. This paper analyzed the conflicts of interest in the achievements translation in hospitals, and considered that conflicts of interest are widespread in practice. Under the background of encouraging innovation and promoting the achievements translation, projects with conflicts of interest should be carried out in hospitals conditionally. While reducing the conflicts of interest, the achievements translation should be done properly.

6.
Chinese Journal of Hospital Administration ; (12): 846-848, 2019.
Article in Chinese | WPRIM | ID: wpr-792226

ABSTRACT

With the constant growth of national investment in science and technology,biomedical scientific and technological achievements keep mushrooming.Hospitals,as a powerful force in high-tech research and development,experimental translation and industrialization of biomedicine research,play an important role in the transfer and translation of scientific and technological achievements.This paper analyzed the conflicts of interest in the achievements translation in hospitals,and considered that conflicts of interest are widespread in practice.Under the background of encouraging innovation and promoting the achievements translation,projects with conflicts of interest should be carried out in hospitals conditionally.While reducing the conflicts of interest,the achievements translation should be done properly.

7.
Article in English | IMSEAR | ID: sea-167187

ABSTRACT

ABSTRACT: Background: Expenditure on industry products (mostly drugs and devices) has spiraled over the last 15 years and accounts for substantial part of healthcare expenditure. The enormous financial interests involved in the development and marketing of drugs and devices may have given excessive power to these industries to influence medical research, policy, and practice. Material and methods: Review of the literature and analysis of the multiple pathways through which the industry has directly or indirectly infiltrated the broader healthcare systems. We present the analysis of the industry influences at the following levels: (i) evidence base production, (ii) evidence synthesis, (iii) understanding of safety and harms issues, (iv) cost-effectiveness evaluation, (v) clinical practice guidelines formation, (vi) healthcare professional education, (vii) healthcare practice, (viii) healthcare consumer‘s decisions. Results: We located abundance of consistent evidence demonstrating that the industry has created means to intervene in all steps of the processes that determine healthcare research, strategy, expenditure, practice and education. As a result of these interferences, the benefits of drugs and other products are often exaggerated and their potential harms are downplayed, and clinical guidelines, medical practice, and healthcare expenditure decisions are biased. Conclusion: To serve its interests, the industry masterfully influences evidence base production, evidence synthesis, understanding of harms issues, cost-effectiveness evaluations, clinical practice guidelines and Healthcare professional education and also exerts direct influences on professional decisions and health consumers. There is an urgent need for regulation and other action towards redefining the mission of medicine towards a more objective and patient-, population- and society-benefit direction that is free from conflict of interests.

8.
São Paulo; s.n; 2014. 110 p.
Thesis in Portuguese | LILACS | ID: lil-790642

ABSTRACT

Introdução. O modelo tecnocrático de assistência ao parto e nascimento propõe uma lógica organizacional com práticas não baseadas em evidências científicas cujos desfechos se contrapõem ao bem-estar materno e infantil. No setor público ocorrem partos com excesso de intervenções e altas taxas de cesarianas. No setor privado, a maioria das mulheres é submetida a cesáreas. Em ambas as situações, pergunta-se a quem e por que é vantajoso o que se prescreve. Objetivos. Revisar sistematicamente a produção científica nacional e internacional que trata das circunstâncias em que o tema dos conflitos de interesses nas indicações de cesárea é abordado. Material e método. Revisão sistemática abrangente da literatura disponível, segundo a metodologia do Instituto Joanna Briggs. Resultados. Foram identificados 4.135 textos em 4 bases de dados - The Cochrane Library, EconPapers, CINAHL e Medline - dos quais 41 foram analisados após a aplicação de critérios.de inclusão. Os idiomas encontrados foram: inglês, francês, português e espanhol, com predominância do primeiro. A maioria trouxe a palavra cesárea entre seus descritores. Foram recorrentes termos ligados à prática de profissionais e às diferentes formas de pagamento ou financiamento da assistência. As influências sobre a decisão por cesárea são abordadas em diferentes análises da assistência.


Background. The technocratic model of childbirth care proposes a logical organizational with non-evidence based practices whose outcomes oppose the welfare of both mother and child. In the public sector births occur with excessive interventions and high rates of caesarean section. In the private sector, the majority of women are subjected to caesarean sections. In both situations, the question is to whom and why it is advantageous to perform those practices. Objectives. To review systematically national and international scientific literature which addresses the circumstances in which the issue of conflicts of interest in indications for cesarean section is approached Material and method. Comprehensive systematic review of the available literature, according to the methodology of the Joanna Briggs Institute. Results. 4,135 texts were identified in four data bases The Cochrane Library, EconPapers, CINAHL, Medline - of which 41 were analyzed after applying inclusion criteria. Languages found were English, French, Portuguese and Spanish, English being the most common.


Subject(s)
Anesthesia, Obstetrical/instrumentation , Conflict of Interest , Cesarean Section/instrumentation , Decision Making , Professional-Patient Relations/ethics , Review
9.
Acta bioeth ; 15(2): 157-164, nov. 2009.
Article in Spanish | LILACS | ID: lil-581953

ABSTRACT

Exponemos una definición de lo que entendemos por conflicto de intereses y la influencia que puede tener esta situación mal manejada sobre la relación médico-paciente. Se proporcionan antecedentes que permiten concluir que el conflicto fundamental en la relación clínica es la llamada doble agencia del médico. La bibliografía última en el tema se ha desatado como consecuencia del sistema conocido en Estados Unidos con el nombre de Managed Care. Esa expresión se ha traducido de varios modos: en nuestro medio se conoce como Gestión Clínica. La expresión norteamericana es muy precisa, porque en sus dos palabras quiere significar las dos funciones fundamentales del clínico: de una parte, su obligación de care y, por tanto, de buscar lo mejor para su paciente; de otra, su condición de manager, es decir, de gestor de recursos, y la necesidad de que mire por el control del gasto. Este es el tema de la llamada doble agencia del médico. Con este nuevo escenario va a cambiar radicalmente el futuro de la profesión médica, en cuya construcción nos parece que los profesionales tienen una responsabilidad indelegable. Estamos a las puertas de un cambio de paradigma en la forma de ejercer la medicina, lo que de todos modos significará un cambio en el contrato social de nuestra profesión.


We want to define what we understand as a conflict of interests and its influence upon the relationship doctor-patient when ill managed. We offer antecedents that allow us to infer that the fundamental conflict in the clinical relationship is the so called doctor's double agency. Bibliography on the subject has increased as a consequence of the system known in the United States as Managed Care. This expression is very precise because its two words imply the two fundamental definitions of a clinician: on one hand, his obligation to care and, therefore, to do his best for his patient; on the other hand, his condition of manager, that is to say, the manager of resources and his need to look over the financial control. This is the subject of the so called doctor's double agency. This new scenery will change the future of the medical profession and we think doctors have an undeniable responsibility. We are at the verge of a paradigmatic change in medical practice which will also mean a change in the social contract of our profession.


Expomos uma definição do que entendemos por conflito de interesses e a influência que pode ter esta situação mal administrada sobre a relação médico-paciente. São proporcionados antecedentes que permitem concluir que o conflito fundamental na relação clínica é a chamada dupla militância do médico. Foi desatada a última bibliografia do tema como consequência do sistema conhecido nos Estados Unidos pelo nome de Managed Care. Essa expressão foi traduzida de vários modos: em nosso meio se conhece como Gestão Clínica. A expressão norte-americana é muito precisa, porque suas duas palavras querem significar as duas funções fundamentais do clínico: de uma parte, a obrigação de care e, portanto, de buscar o melhor para seu paciente; de outra, a condição de manager, quer dizer, de gestor de recursos e da necessidade de que mire no controle do gasto. Este é o tema da chamada "dupla militância do médico". Este novo cenário vai mudar radicalmente o futuro da profissão médica, em cuja construção, segundo nos parece, os profissionais têm uma responsabilidade indelegável. Estamos às portas de uma mudança de paradigma na forma de exercer a medicina que, de todos os modos, significará uma mudança no contrato social de nossa profissão.


Subject(s)
Bioethics , Conflict of Interest , Health Management
10.
Brasília méd ; 46(supl.1)2009.
Article in Portuguese | LILACS | ID: lil-540121

ABSTRACT

A pesquisa clínica constitui o principal meio para avaliação da eficácia e segurança de novos medicamentos e outras tecnologias médicas. Ainda que os ensaios clínicos estejam se desenvolvendo de maneira muito mais segura e ética do que se observava há décadas atrás, a eliminação de abusos grosseiros traz à tona alguns problemas éticos. Este artigo enfatiza dois grandes problemas éticos e desafios envolvidos na condução da pesquisa clínica: o conflito de interesses e a obtenção do consentimento informado. A maioria dos ensaios clínicos é financiada por indústrias farmacêuticas que apostam volumosas quantias nos produtos sendo avaliados. Além do mais, os cientistas que desenham, conduzem, analisam e publicam os resultados frequentemente recebem compensações financeiras pelas indústrias, tanto na forma de salário como taxas de aconselhamento. O consentimento é o processo pelo qual o paciente é informado e torna-se um participante nas decisões sobre seu manejo clínico. Argumenta-se, entretanto, que a obtenção da assinatura do participante no documento de consentimento informado adiciona muito pouco na qualidade do processo de consentimento. Este artigo também sugere medidas para assegurar a conduta científica e ética apropriada para ensaios clínicos.


Clinical trials are the primary means to evaluate the efficacy and safety of new drugs and other medical technologies. Although clinical trials are conducted far more ethically and safer now than they were some decades ago, the elimination of gross abuses has tended to highlight more subtle ethical problems. This review highlights two major ethical problems and challenges involved in the conduct of clinical trials: conflict of interest and consent process. Most clinical trials are funded by pharmaceutical companies with enormous financial stakes in the products being evaluated. Furthermore, the scientists who design, conduct, analyze, and report clinical trials often receive monetary compensation from drug companies, in the form of either salaries or consulting fees. Consent is a process by which a patient is informed and becomes a participant in decisions regarding their medical management. It is argued, however, that providing a signature to a form adds little to the quality of this process. This review also suggests measures to ensure scientifically and ethically sound clinical trials.


Subject(s)
Humans , Conflict of Interest , Informed Consent , Informed Consent/ethics , Clinical Trials as Topic/ethics , Biomedical Research , Ethics, Research
11.
Interface comun. saúde educ ; 12(27): 893-905, out.-dez. 2008.
Article in Portuguese | LILACS | ID: lil-502923

ABSTRACT

A indústria farmacêutica utiliza a propaganda para a promoção de seus produtos. Os de uso controlado só podem ter a propaganda dirigida a profissionais habilitados a prescrevê-los ou dispensá-los. Este artigo faz uma ampla revisão de artigos científicos que discutem questões éticas e legais acerca da promoção e propaganda de medicamentos em ambientes de ensino médico. Conclui-se que não se justifica a auto-regulamentação da propaganda de medicamentos e que existem evidências suficientes de como o poder da indústria farmacêutica é capaz de influenciar as decisões no âmbito da relação médico-paciente, sendo a promoção e a propaganda um de seus instrumentos. Defende-se sua total proibição em ambientes de ensino, bem como a incorporação da temática na formação dos estudantes. Como a legislação vigente permite a propaganda de medicamentos vendidos sob prescrição apenas a médicos e farmacêuticos, destaca-se que tal propaganda é ilegal quando atinge estudantes de medicina e de farmácia.


The pharmaceutical industry uses advertising to promote its products. Controlled drugs can only be advertised to professionals who are licensed to prescribe or dispense them. This paper makes an extensive review of scientific articles that discuss the ethical and legal implications of drug promotion and advertising in medical teaching environments. It concludes that self-regulation of drug advertising is not justified and that there is sufficient evidence showing how the power of the pharmaceutical industry is capable of influencing decisions made within the physician-patient relationship, in which promotion and advertising are among the tools used. This paper advocates complete prohibition of drug promotion and advertising in teaching environments, and the incorporation of this issue in students' education. Given that the current legislation permits advertising of prescription drugs only to physicians and pharmacists, it is emphasized that such advertising is illegal when it reaches medical and pharmacy students.


La industria farmacêutica utilizada la propaganda para la promoción de sus productos. Los de uso controlado sólo pueden tener la propaganda dirigida a profesionales habilitados a prescribirlos o despacharlos. Este artículo hace una amplia revisión de artículos científicos que discuten cuestiones éticas y legales acerca de la promoción y propaganda de medicamentos en ambientes de enseñanza médica. Se concluyó que no se justifica la auto-reglamentación de la propaganda de medicamentos y que existen evidencias suficientes de como el poder de la industria farmacéutica es capaz de influir en las decisiones en el ámbito de la relación médico-paciente, siendo la promoción y la propaganda uno de sus instrumentos. Se defiende su total prohibición en ambientes de enseñanza, así como la incorporación de la temática en la formación de los estudiantes. Como la legislación vigente permite la propaganda de medicamentos vendidos bajo prescripción solamente a médicos y a farmacéuticos, se resalta que tal propaganda es ilegal cuando alcanza a los estudiantes de medicina y farmacia.


Subject(s)
Drug Publicity , Universities , Drug Industry/ethics , Drug Industry/legislation & jurisprudence
12.
China Pharmacy ; (12)2005.
Article in Chinese | WPRIM | ID: wpr-532664

ABSTRACT

OBJECTIVE:To put forward suggestions for the legal regulation on the financial conflict of interest of researchers in drug clinical trials.METHODS:The definition and harm of the financial conflict of interest of the researchers in clinical trials were analyzed,and the legal measures of FDA on regulating and controlling the financial conflict of interest of the researchers were evaluated.RESULTS & CONCLUSIONS:The Chinese legislature should draw useful legal experiences from USA to establish suitable legal measures to regulate and control the financial conflict of interest of researchers in clinical trials,clarify the definition of the financial interest of researchers,require the applicant for clinical trial to disclose his financial interest and the applicants for drug registration to submit the statement about the financial conflict of interest of researchers to the drug administration department.

13.
Chinese Medical Ethics ; (6)1995.
Article in Chinese | WPRIM | ID: wpr-527643

ABSTRACT

Presently there is co-existed of over-and deficient treatment in percutaneous coronary intervention in china and the conflict of interest between doctors and patients among which mainly appeared to be financial conflict.The conflict is resulted from deviation of direction in reformation of economy policy,mismatched conditions between medical ethics and medical technique,misunderstanding between doctors and patients.In this paper we discussed the resolving methods,including enhancing healthy economy reformation,establishing harmonious relationship between doctors and patients,optimizing the utilizing of interventional technique.We also must persist in justice and public good principle.Undoubtedly to say conflict of interests between doctors and patients always exists,the way to minimize it relay on co-exertion of society,governmental control agency,doctors and patients,and this will take a long time.

SELECTION OF CITATIONS
SEARCH DETAIL